EXAGEN INC

Company Overview

Exagen is a specialty clinical laboratory (Diagnostics & Research) focused on the AVISE portfolio of laboratory tests for complex rheumatic and autoimmune diseases, with AVISE CTD representing ~90% of 2024 revenue. Tests are run in a single CLIA/CAP‑accredited lab in Vista, CA and sold primarily to ~6,000 U.S. rheumatologists via a 40‑territory field force plus inside sales; 2024 revenue was $55.6M with gross margin near 59–60% and improving unit economics. Recent commercial activity includes the January 2025 launch of T‑cell and RA sub‑profile biomarkers and planned PAD4 and lupus nephritis launches, while key risks are payor coverage/reimbursement, supplier concentration, and evolving regulation of LDTs and medical devices.

Executive Compensation Practices

Compensation is likely tied to commercial and reimbursement metrics: revenue, ASPs (recently increased), gross margin/adjusted EBITDA, successful reimbursement outcomes (MolDX/PLA/LCD), and commercial milestones for newly launched biomarkers. Typical sector practice—reflected in Exagen’s filings—uses a mix of salaries, cash bonuses tied to near‑term financial targets, and equity incentives (options/RSUs) aligned to long‑term product launches, IP milestones and clinical validation; the company explicitly reduced stock‑based compensation in 2024 to lower SG&A. Given the capital‑constrained profile (accumulated deficit, loan covenants, periodic equity raises), boards may favor cash conservation, milestone‑based LTIP vesting and retention awards tied to financing or covenant compliance. R&D progress (validation of T‑cell/RA/PAD4 assays) and regulatory/reimbursement wins will be primary drivers for large equity payouts.

Insider Trading Considerations

Insider trading at Exagen will likely cluster around binary, high‑information events—earnings, reimbursement/LCD decisions, FDA/agency developments on LDT regulation, and biomarker commercialization or clinical validation readouts—because those events materially change revenue and cash runway expectations. The company’s small product concentration (AVISE CTD), single lab operations and supplier dependencies increase the likelihood that material non‑public operational events drive sharp stock moves, so insiders should observe strict blackout windows and consider 10b5‑1 plans to avoid allegations of trading on material non‑public information. Financing events (public offering May 2025, Perceptive term loan) and covenant triggers also influence insider behavior: insiders often sell into equity raises or are restricted by investor agreements, and compensation design (reduced SBC, milestone vesting) may reduce opportunistic selling but increase sensitivity to dilution and timing of trades.